This prospective study aims to characterize blood brain barrier (BBB) disruption in patients with newly diagnosed glioblastoma multiforme undergoing surgical resection. The study integrates advanced MRI, circulating BBB biomarkers, neurocognitive assessment, and molecular analysis of tumor tissue to investigate relationships between BBB integrity, tumor biology, and neurological function. Participants will undergo serial assessments before surgery, after surgery, and following radiotherapy. Tumor tissue collected during standard-of-care resection will undergo immunohistochemical and transcriptional
Adult patients aged 18 years or older.
Newly diagnosed glioblastoma.
Selected for surgical tumor resection.
Able and willing to provide written informed consent.
Contraindication to magnetic resonance imaging.
Confusion, delirium, or altered state of consciousness that interferes with the ability to provide informed consent.
Any condition that, in the opinion of the investigator, would prevent completion of study procedures or compromise participant safety.
Patrick Morris
Lead sponsor
Beaumont Hospital
Sponsor institution